Summary
Dr. Wang's laboratory conducts basic and translational research on oncogenic protein kinases, with a focus on diacylglycerol-regulated kinases, cell cycle checkpoint kinases, and the development of targeted cancer therapies against these enzymes. Her work combines molecular, cellular, genetic, and in vivo approaches to uncover the roles of these kinases in cancer progression, particularly in prostate cancer. The lab has pioneered the development of selective PKD inhibitors with in vivo efficacy, advancing them as potential targeted therapies for cancer. Her research bridges cancer biology and drug discovery to drive new therapeutic strategies.